KR100857896B1 - Composition for improving allergy containing clematidis radix extract - Google Patents

Abstract

A composition containing the extract of Clematidis radix is provided to improve allergy symptoms including atopic dermatitis or asthma by applying it orally or transdermally, and enhance safety of use by inhibiting side effects. A composition for improving allergy symptoms, including atopic dermatitis, asthma, conjunctivitis, rhinitis, urticaria and food allergy, contains the extract of Clematidis radix which is prepared by preparing Clematidis radix or pulverized Clematidis radix, extracting Clematidis radix with lower alcohol to obtain a crude extract, and fractionating the crude extract with n-butanol.

Description

Composition for improving allergy containing Clematis radix extract

1 is a photograph evaluating the effect of allergic symptoms of gastric saponin-rich fractions.

The present invention relates to a composition for improving allergy, such as atopic dermatitis, asthma, and a method for producing a plant extract useful for allergy improvement, characterized by containing a plant extract.

Atopy is a Greek word for "a-topos," meaning unusual, unusual, unusual reactions, strange, unknown meanings, etc. Literally, atopy is a complex entanglement of a variety of causes, repeated remission and relapse. Complex and diverse causes mean that treatment is difficult. Allergy in Korean is interpreted the same as atopy, which has a more complex meaning than allergy. In 1923, Cooke and Coca of the United States began to call atopic diseases to distinguish allergic diseases with genetic predispositions from other allergic diseases, and to call atopy for the genetic tendency of these diseases. In other words, atopy is a type of allergic disease that, unlike the common allergic symptoms, tends to be genetic. In other words, atopy is defined as a series of allergic symptoms that occur in the skin, respiratory mucosa, eye mucosa, and intestinal mucosa in individuals with atopic predisposition. Atopic disease, and asthma, conjunctivitis, dermatitis, etc. These diseases are alone or there several diseases can appear simultaneously generally have atopic dermatitis can be said that a representative example (Kim Jung Hee, the latest findings of atopic dermatitis, Pediatric Allergy and Respiratory Diseases, 14, 12-23, 2004 ).

The cause of atopic dermatitis has not yet been reliably identified, and since the clinical symptoms are variously expressed in dry skin, eczema, etc., the pathogenesis can not be explained by any one of them. . Generally allergic symptoms such as asthma, rhinitis, urticaria, etc. are often accompanied, and family history has a high incidence of genetic predisposition, but it is estimated to have multifactorial deterioration factors by individual such as living environment and emotional state. There is this. The main symptom of atopic dermatitis is itching, and when itchy and scratched, it develops into eczematous lesions, and as the lesion progresses, a series of vicious cycles occur, causing further pruritus. Therefore, the most important treatment in these patients is to get rid of itching in some way.

On the other hand, when foreign substances such as bacteria or viruses invade from the outside, the human body is equipped with an immune system that is a biological defense mechanism to protect the body against them, and allergic diseases occur because this immune system is excessively acting. These allergic diseases are caused by recent air pollution, changes in diet, physical or mental stress, environmental changes such as indoor pollution due to changes in living environment, or changes in human constitution, but the causes are very diverse and unclear.

Such allergic diseases include asthma, atopic dermatitis, allergic conjunctivitis, allergic rhinitis such as hay fever, and food allergies. In particular, atopic dermatitis is annoying not only to patients but also to parents because of the itching during infancy. Most of the time, it is better before adulthood, but if it continues until adulthood, the skin of the face, chest, elbow or the inside of the knee becomes thick and itchy. Get up and tease adolescents. For the treatment of atopic dermatitis, external therapy is the main method, and depending on the symptoms, corticosteroids, antihistamines, fatty acid supplements, and other anti-inflammatory agents are used. However, these therapies do not cure allergic diseases as symptomatic therapy, and the side effects of using the medicine are also known to be serious.

Chemokines have been included as important mediators of allergic, inflammatory and autoimmune disorders and diseases such as asthma, atherosclerosis, glomerulonephritis, pancreatitis, restenosis, rheumatoid arthritis, diabetic nephropathy, pulmonary fibrosis and transplant rejection. Thus, the use of antagonists of chemokine function may help reverse or hinder the progression of the disorder and disease. In particular, elevated expression of MCP-1 (Monocyte Chemotactic Protein-1) has been observed in many chronic inflammatory diseases [ Proost et al . , Int . J. Clin . Lab . Res ., 26: 211-223 (1996); Taub DD, Cytokine Growth Factor Rev., 7: 355-376 (1996) ], and was also observed in rheumatoid arthritis included in the disease [ Robinson et al. Clin Exp Immunol , 101: 398-407 (1995); Hosaka et al . , Ibid . 97: 451-457 (1994); Koch et al . , J. Clin . Invest ., 90: 772-779 (1992); Villiger et al . , J. Immunol ., 149: 722-727 (1992) ] and have also been observed in asthma [ Hsieh et al., J. Allergy Clin . Immunol., 98: 580-587 (1996); Alam et al . , Am . J. Respir . Crit . Care Med ., 153: 1398-1404 (1996); Kurashima et al., J. Leukocyte Biol ., 59: 313-316 (1996); Sugiyama et al . , Eur . Respir . J., 8: 1084-1090 (1995) ] and also observed in psoriasis [ Gillitzer R et al., J. Invest . Dermatol ., 101-127 (1993) ], and anti-MCP-1 antibodies were also shown to have inhibitory and therapeutic effects in mouse animal models [Rand ML et al., Am. J. Pathol., 148: 855 (1996). MCP-1 is also a chemokine made by macrophages, smooth muscle cells, fibroblasts and vascular endothelial cells, and regulates histamine release by basophils as well as cell migration and cell binding of monocytes, memory T cells, and natural killer cells. It has also been reported to cause [ Rollins BJ et al., Proc. Natl . Acad . Sci ., 85: 3738-3742 (1988); Matsushima K et al . , J. Exp . Med., 169: 1485-1490 (1989); Jiang Y et al . , Am . J. Physiol ., 267: C1112- C1118 (1994); Allavena P et al . , Eur . J. Immunol ., 24: 3233-3236 (1994) . MCP-1 also increases the IgE and IgG4 immunoglobulin production plays an important role in the allergic response thereto for antagonists has been reported that it can play an important role in the improvement and treatment of allergic symptoms, allergic [Kaplan AP et al . , Exp . Dermatol ., 4 (4): 260-265 (1995); Kimata H et al . , J. Exp . Med ., 183: 2397 (1996); Giampiero G et al . , Curr . Opinion Immunol ., 13 (6): 733- 737 (2001); Romagnani S et al . , Mol . Immunol ., 38 (12-13): 881-885 (2002); Pierre - Olivier F et al . , J. Allergy & Clin . Immunol ., 118 (2): 536-538 (2006); Martin S et al. , J. Allergy & Clin. Immunol ., 118 (1): 190-197 (2006) ]. Therefore, it is clear that a suitable MCP-1 antagonist or MCP-1 inhibitor is a very effective method for the effective treatment of allergic symptoms such as atopic dermatitis and asthma.

Recently, many studies have been published to improve allergy symptoms using natural materials. Korean Patent Application No. 10-2003-0077911 discloses a food additive, an animal feed additive or a cosmetic composition containing a worm extract having anti-allergic and anti-inflammatory activity, and in Korea Patent Application No. 10-2004-0000781 It is disclosed that the atopic skin disease healing effect of the skin cosmetic composition containing plant extracts obtained from baeknyeoncho, etc. as a specific plant extract is excellent. Patent application No. 10-2004-0011984 discloses atopic dermatitis or dryness using the extract of There is also disclosed a composition for use in therapy.

As described above, there have been many attempts to develop a therapeutic agent for improving allergic symptoms from various natural plant resources, but most of them use crude extract extracted using water or ethanol as an extraction solvent, and the effect is weaker than expected. Or it is known that there are many cases of unexpected side effects due to the use of crude extract to contain a lot of unnecessary components.

Therefore, the technical problem to be achieved by the present invention is to provide a composition having fewer side effects and safe allergy improvement effect, and pharmaceuticals, functional foods or cosmetics containing the same.

Another technical problem to be achieved by the present invention is to provide a method for preparing a gastric extract of a safe yet excellent allergic effect.

In order to achieve the above technical problem, the present invention provides a composition for improving allergy, characterized in that it contains the gastric extract as an active ingredient, more preferably, the gastric extract is saponin-rich fraction or gastric gland lower alcohol extract of the gastric extract The n-butanol fraction provides an allergy improving composition.

The present invention also comprises the steps of (S1) preparing a gasoline or crushed gasoline; (S2) extracting the gastric gland with lower alcohol to obtain a gastric gland extract; (S3) provides a method for producing a safe and allergic effect of the above-mentioned gastric gland extract, characterized in that it comprises the step of extracting the gastric gland extract as n-butanol.

Hereinafter, the method for preparing a gastric extract of the present invention and a method for preparing a gastric extract excellent in safety and allergy improvement will be described in more detail.

Radix Clematidis is a perennial deciduous plant belonging to the Ranunculaceae family, Clematis mandshurica MAXIM., Clematis mandshurica RUPR., Clematis brachyura MAXIM. (Clematis paniculate THUNB.), Clematis florida THUNB., Clematis patens MORREN. And dried roots and rhizomes of related plants. In China, the clematis chinensis OSBECK. Originated with Clematis hexapetala PALL. These wiryeongseon is known to be, such as analgesic action, anti-malarial action, antibacterial action, action heritage, bile secretion promoting action, smooth muscle relaxing action, an anti-diuretic, cardiac and blood pressure lowering action [Chinese Materia Medica , Chemistry, Pharmacology and Applications , You - Ping Zhu , 1998 ].

The composition for allergy improvement of the present invention includes a saponin-rich fraction or an n-butanol fraction of a gastric liquor lower alcohol extract of a gastric extract, preferably a safe and allergic effect, as an active ingredient.

In the California Poison Control System (www.calpoison.org) of the United States, among the poisonous plants, the gastrointestinal tract may cause toxicity, such as vomiting or diarrhea when ingested, or may cause redness and irritation upon skin contact. Is classified as a very severe and painful plant, and the U.S. Food and Drug Administration is classified as a toxic plant and designated as a plant that needs attention when used. Therefore, the study of obtaining a safe extract from these gastric vessels is essential, there is a risk of gastrointestinal toxicity or skin toxicity in the case of conventional extracts.

The present invention is based on the surprising fact that the saponin-rich fractions among the gastric extracts have no side effects than the conventional extracts, and the allergic improvement effect is significantly improved, and the n-butanol fraction of the crude gastric extracts is rich in saponins and has fewer side effects and allergy improvement. It's based on the amazing fact that it works. Therefore, the allergy improvement composition of the present invention more preferably contains a saponin-rich fraction in the gastric extract of the stomach as an active ingredient.

Saponin-rich fraction of the gastric gland extract is prepared by (S1) gastric gland or crushed gastric gland; (S2) extracting the gastric gland with lower alcohol to obtain a gastric gland extract; (S3) it can be prepared by a manufacturing method comprising the step of extracting the extract of the gastric gland to n-butanol.

However, the saponin-rich fraction of the present invention is not limited to that obtained by the above production method, and any solvent may be used as long as the saponin-rich fraction is prepared to contain abundant saponin components by repeating the solvent extraction process.

Maeseran extract can be extracted using a common solvent extraction method using available solvents such as water, ethanol, methanol, butanol, chloroform, dichloromethane, hexane, ethyl acetate, or also obtained by supercritical carbon dioxide extraction method. It can also refine | purify with higher purity by refine | purifying the obtained thing again.

The allergy improving composition of the present invention can be prepared in the form of pharmaceuticals, functional foods and cosmetics. Such pharmaceuticals, nutraceuticals and cosmetics may comprise pharmaceutically acceptable excipients or additives. The allergy improving composition of the present invention may be administered alone or in admixture with any convenient carrier, excipient, etc., and such dosage forms may be single or repeated dose formulations.

Medicines, functional foods or cosmetics containing the allergy improving composition of the present invention may be a solid preparation, a semisolid preparation or a liquid preparation. Solid preparations include, but are not limited to, powders, granules, tablets, capsules, suppositories, and the like. Solid form preparations may include, but are not limited to, excipients, flavors, binders, preservatives, disintegrants, lubricants, fillers and the like. Semi-solid preparations include, but are not limited to, creams, lotions, emulsifiers, lining agents, and the like, and may be prepared by adding suitable colorants, flavoring agents, stabilizers, viscosity agents, surfactants, and the like. Liquid formulations include, but are not limited to, solutions such as water, alcohols, propylene glycol solutions, suspensions, emulsions, and the like, and may be prepared by adding suitable colorants, flavors, stabilizers, viscosity agents, and the like.

The allergy symptom improving composition of the present invention may be administered orally, by injection (eg, intramuscular injection, intraperitoneal injection, intravenous injection, infusion, subcutaneous injection, implant), inhalant, nasal cavity, depending on the condition to be treated and the condition of the individual. Administration, vaginal, rectal, sublingual, transdermal, topical, etc. may be administered, but is not limited thereto. It may be formulated into a suitable dosage unit dosage form comprising a pharmaceutically acceptable carrier, excipient, vehicle, conventionally used and nontoxic, depending on the route of administration. Depot formulations capable of continually releasing the drug for a period of time are also within the scope of the present invention.

Gastric saponin-rich fraction of the present invention may be administered daily from about 0.01 mg / kg to about 10 g / kg to achieve the purpose of improving the allergy symptom, and from about 0.1 mg / kg to about 1 g / kg Daily doses are preferred. However, the dosage may vary depending on the route and formulation of administration, the condition of the patient (age, sex, weight, etc.), the severity of the condition being treated, the content of the saponin-rich fraction of the gastric gland according to the extraction method, and the like. If desired, the total daily dose may be divided for convenience and divided several times throughout the day.

Allergic diseases in which the gastric gland extract of the present invention can be used include atopic dermatitis, asthma, conjunctivitis, rhinitis, urticaria, food allergies and the like.

Hereinafter, the following examples and the like will be described in order to describe the present invention in more detail. However, embodiments according to the present invention may be modified in many different forms and the scope of the present invention should not be construed as being limited to the embodiments described below. Embodiments of the present invention are provided by way of example in order to facilitate a specific understanding of the present invention.

<Example 1> Preparation of crude gasoline extract

Purchasing and crushing the gastric roots of the stomach, and adding about 3L of 70% methanol per 1Kg weight and extracted three times at room temperature for 3 days, and the filtrate was concentrated under reduced pressure at 45 ℃ with a rotary pressure reducer The crude extract was obtained by passing through. Solid content was 8.58% at this time.

Example 2 Preparation of Saponin-Rich Fraction of Gastric Gland

The gastric extract obtained in Example 1 was extracted three times with water (1 L) and ethyl acetate (1 L), and the water layer was extracted three times with n -butanol (1 L). Each layer was concentrated under reduced pressure to obtain an ethyl acetate fraction, n -butanol fraction and water fraction. Among them, n -butanol fractions were identified using TLC. CHCl ₃ : MeOH: H ₂ O = 65: 35: 10 was used as the TLC developing solvent for the n -butanol fraction, and the sample was adsorbed into a TLC chamber containing a prepared solvent, developed, and dried. It was confirmed that the n -butanol fraction was saponin-rich fraction containing a large amount of saponins in the n -butanol fraction by dipping in an aqueous solution of% H ₂ SO ₄ and drying and heating. At this time, the yield was 2.14%.

<Prescription Example 1> Preparation of Cream

The saponin-rich fraction of the gastric gland prepared in this way can be applied through all routes of administration including oral or transdermal, but in the present invention, in order to evaluate the improvement effect of allergy symptoms, the cream formulation of Table 1 was prepared and evaluated. The present invention is not limited to the examples below, and oral preparations such as lotions, soaps, packs, lotions, ointments, suspensions, emulsifiers, or tablets, liquids, capsules, granules, powders, injections, suspensions, emulsifiers, and the like. All formulations may be included.

Prescription Example 1 Control Colonel Saponin-Rich Fraction 3.0 - Polyethylene Glycol Monostearate 2.0 2.0 Self-emulsifying glycerin monostearate 5.0 5.0 Cetyl alcohol 4.0 4.0 Squalene 6.0 6.0 Tri2-ethylhexaneglyceryl 6.0 6.0 Sphingoglycolipid 1.0 1.0 1,3, -butylene glycol 7.0 7.0 Add 100 ml of purified water

Example 3 Cytokine Inhibitory Activity Related to Allergy Symptoms of Gastric Gland Extract and Saponin-Rich Fraction

(1) Inhibition of IL-1beta and TNF-alpha Production

Human synovial cells were secondary cultured (1 × 10 ⁵ cells / ml) 3 days before the experiment, and 2 × 10 ⁶ cells were dispensed into each well in a 12 well plate, followed by fetal bovine serum deficient RPMI-1640 medium. Incubated for 12 hours. Treated gastric crude extract (10mcg / ml) and saponin-rich fractions (10 or 1mcg / ml) and after 1 hour rhIL-1beta (100U / ml) and rhTNF-alpha (100ng / ml) were added to each well It was. After 6 hours, each well was washed with RPMI-1640 culture solution, treated with fresh culture medium, gastric crude extract, and saponin-rich fractions, and incubated in a CO ₂ incubator for 48 hours. After the completion of the culture, the whole culture solution was centrifuged at 2000 rpm for 5 minutes to recover the supernatant, and the yield was measured using an ELISA kit. The results are shown in Table 2 below. As shown in Table 2, it was confirmed that gastric saponin-rich fractions inhibit IL-1beta and TNF-alpha secretion more strongly than crude gastric extract.

Cytokine Measurement Sample Cytokine Production (pg / ml) IL-1beta Control 88.2 ± 14.8 Crude Extract 10mcg / ml 56.0 ± 12.7 * Saponin-rich fraction 1mcg / ml 43.1 ± 9.3 * Saponin-rich fraction 10mcg / ml 34.2 ± 8.7 * Control 1843 ± 183.5 TNF-alpha Crude Extract 10mcg / ml 1501 ± 103.1 * Saponin-rich fraction 1mcg / ml 1345 ± 131.0 * Saponin-rich fraction 10mcg / ml 1274 ± 97.8 *

In Table 2, * means that there is a significant difference at p <0.05.

(2) Inhibition of MCP-1 Production

The sandwich ELISA method was used to confirm the binding inhibitory activity of MCP-1 and its receptor CCR2. This is a method of confirming indirect binding inhibitory activity by measuring the amount of MCP-1 that is not bound after reacting MCP-1 with cells. MCP-1 capture antibody (capture antibody, anti-hMCP-1 antibody, diluted 1: 250 with PBS) was added to a 96-well ELISA plate and coated at 4 ° C. for 24 hours. 100 ul of blocking solution (1% BSA, 5% sucrose, 0.05% NaN 3 PBS) was added and blocked at 37 ° C. for 1 hour, followed by three washes with wash solution (PBS with 0.05% Tween-20). THP-1 cells were suspended in HEPES buffer (50 mM HEPES, 1 mM CaCl ₂ , 5 mM MgCl ₂ , 150 mM NaCl, 0.5% BSA, pH7.2), followed by rhMCP-1 (1 nM), gastric crude extract (5ul) and gastric gland Saponin-rich fractions (5ul) were added and reacted at 37 ° C for 1 hour. After reaction, 100 ul of supernatant was added to 96-well ELISA plates coated with capture antibody. After incubation for 2 hours at room temperature, the plate was washed, treated with biotin-attached anti-hMCP-1 antibody (1: 5000 dilution, 1 ng / well), reacted for another 2 hours at room temperature, and the plate was washed again and strep Tavidine (streptavidin) -HRP (1: 1000 dilution, 1ug / ml) was added and incubated for 20 minutes at room temperature. The plates were washed and then incubated for 30 minutes at room temperature with the addition of peroxidase substrate reagent (100ul / well). The reaction was stopped by the addition of 50ul of stop solution (3M H ₂ SO ₄ ) and the MCP-1 was measured at 450nm with a microplate reader. As a result of measuring the inhibitory effect of MCP-1 activity with a final concentration of 25 g / ml of gasoline crude extract and saponin-rich fractions, the control group not treated with the gastric extract showed about 4.3% of the inhibitory activity. In the group treated with 42.4% of the activity inhibitory effect, the saponin-rich fraction of the gastric liquor was 81.7%, which was about twice as strong as the crude extract.

As such, saponin-rich fractions of gastric glands allergic symptoms by inhibiting the cytokines IL-1beta, TNF-alpha and MCP-1, which are known to be associated with the allergic symptoms, are more strongly than alcoholic extracts of the gastric glands. It was found that it can be usefully used for improvement.

Example 4 Evaluation of Effectiveness on Atopic Dermatitis-1

(1) For 24 patients with atopic dermatitis with a genetic predisposition to atopic dermatitis, the cream preparation prepared in the above-mentioned prescription example was applied for 1 month at the same dosage as a conventional cosmetic.

As a result, 11 out of 24 patients had ameliorated symptoms of atopic dermatitis, 6 had some relief, 4 had minimal effect, and 3 had little change. The relief of the symptoms here means that the itching has subsided and the skin redness has subsided. In neither case, there was no hypersensitivity or side effects caused by cosmetics.

(2) In 20 patients with atopic dermatitis without genetic predisposition of atopic dermatitis, the cream preparation prepared in the above-mentioned prescription example was applied for 1 month at the same dosage as a conventional cosmetic.

As a result, 11 out of 20 had almost recovered from atopic dermatitis, 6 were alleviated considerably, and 3 were alleviated to some extent. The relief of the symptoms here means that the itching has subsided and the skin redness has subsided. In addition, as in the above case, there was no hypersensitivity reaction or side effects caused by cosmetics.

The results of one of the subjects are shown in FIG. 1. 1 is a photograph evaluating the allergic symptoms improvement effect of the saponin-rich fraction of the gastrointestinal tract.

Example 5 Evaluation of Effectiveness on Atopic Dermatitis-2

In order to clinically measure the improvement effect on the atopic skin of the cosmetic composition for improving atopic symptoms presented in Formulation Example 1, the saponin-rich fraction-containing cosmetic composition (prescription example 1) of the gastric gland of the present invention and the cosmetic composition of a conventional prescription ( A clinical trial was conducted with a control regimen containing no gastric saponin-rich fractions. That is, 25 people with simple atopic skin with age distribution of 6 to 50 years old and 15 people with atopic dermatitis irritate itching 2-3 times daily for 15 days. Atopic improvements such as stratum corneum hydration and protective film formation (repair of the barrier), normalization of epidermal metabolism, healing of inflammation, etc. were visually observed and the effects thereof were determined.

A marked improvement Slightly improved No change Worse Conventional prescription (for control) 2 5 24 9 Prescription Containing Saponin-rich Fraction 19 16 5 0

As described above, the gastric gland saponin-rich fraction-containing composition according to the present invention was found to have a very good effect of improving atopic symptoms. From these results, it was confirmed that the gastric saponin-rich fraction-containing allergy symptom improving composition of the present invention has an excellent improvement effect on atopic skin compared to the cosmetics of the conventional prescription.

Example 6 Evaluation of Effectiveness on Asthma

Male subjects 7 and 65 years old with asthma twice daily, morning and evening, 5 mg and 30 mg of the gastrointestinal saponin-rich fraction containing allergic disease of the present invention evenly dispersed in water and then orally After taking about one month, the number of coughs caused by asthma decreased by more than 70% compared to before taking.

Example 7 Skin Stimulation Test

(1) After a certain amount (0.1 g) of the composition of Formulation Example 1 (0.1 g) was closed on the back of 20 subjects using a Finn chamber and Scanpore tape for 24 hours, and then removed, 90 minutes after Stimulation was determined by two experts according to the International Contact Dermatitis Research Group (ICDRG) scale. Judgment criteria are as follows, and the results are shown in Table 4 below.

[Criteria]

(-): No stimulus at all (0 points)

(±): Very weak redness (1 point)

(+): Mild redness (2 points)

(++) Strong redness (3 points)

(+++): Very strong redness or edema (4 points)

Prescription Example 1 Control ICDRG scale 0.07 0.08

Looking at the results, it was confirmed that the composition of Formulation Example 1 and the control formulation is almost no difference in the skin irritation degree, so that the skin irritation by the saponin-rich fraction of the present invention is almost a safe material.

(2) To determine the degree of skin irritation during repeated application, ROAT (Repeated Open Application Test) was performed in parallel. Forearm of 35 subjects was applied with a prescribed amount (0.1 g) of prescription and control composition on each side of the arm, 5 times a week and 2 times a day for 2 weeks. And on the last day of evaluation, the skin irritation of the test site was visually determined and the number of stimuli was counted. The results are shown in Table 5.

Prescription Example Control Irritation 0 0

The results of Table 5 confirm that the gastric gland saponin-rich fraction-containing composition of the present invention is a safe material having almost no skin irritation compared to the control composition even after long-term use.

As such, the present invention provides a composition excellent in improving effects on various conditions caused by an allergic reaction such as atopic dermatitis, asthma and the like, and a medicine, functional food or cosmetics for improving allergic symptoms comprising the same. The present invention also provides a method for preparing a gastric extract, which has fewer side effects and is excellent in allergic effect.

Claims (6)

Allergy improving composition comprising the above extract as an active ingredient. The allergy improving composition according to claim 1, wherein the allergy is atopic dermatitis, asthma, conjunctivitis, rhinitis, urticaria or food allergy. The allergy improving composition according to claim 2, wherein the allergy is atopic dermatitis or asthma. delete The allergy improving composition of claim 1, wherein the extract of the gastric gland is an n-butanol fraction of a lower alcohol extract having 1 to 4 carbon atoms of the gastric gland. delete

Images